非类固醇与类固醇矿物质皮质体受体对手在心力衰竭:现实世界的证据从一个多中心队列研究
Jheng-Yan Wu1,2, Kuan-Jui Tseng3, Yu-Min Lin4
1Department of Nutrition Chi Mei Medical Centre Tainan Taiwan.
Journal of the American Heart Association
|October 23, 2025
概括
与类固醇MRA相比,非类固醇矿物质皮质类受体对抗剂 (MRAs) 显著改善了心力衰竭 (HF) 的结果. 这项现实研究发现,非类固醇MRAs的死亡率,住院和HF恶化较低.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据 现实世界的证据
背景情况:
- 矿物质皮质类受体抗剂 (MRA) 在治疗心力衰竭 (HF),减少死亡率和住院治疗方面至关重要.
- 芬瑞诺,一种新的非类固醇MRA,显示出希望,但在现实世界HF群体中与类固醇MRA的直接比较是有限的.
研究的目的:
- 在心力衰竭患者中,比较非类固醇与类固醇MRA的实际有效性和安全性.
- 评估非类固醇MRA对临床结果的影响,包括死亡率,住院和HF恶化.
主要方法:
- 一个回顾性,倾向性得分匹配的队列研究利用了TrinetX数据库.
- 分析了2021年1月至2025年2月期间开始非类固醇或类固醇MRA的成人HF患者.
- 主要结局是所有原因死亡率,住院和1年后HF恶化的复合结果.
主要成果:
- 在匹配后,每组有1619名患者 (非类固醇与类固醇MRA).
- 非类固醇MRA与明显较低的初级复合结局相关 (HR,0.79;P<0.001).
- 与非类固醇MRA一起观察到所有原因死亡率 (HR,0.49),住院 (HR,0.80) 和恶化HF (HR,0.76) 的风险降低,没有显著的安全差异.
结论:
- 与类固醇MRA相比,非类固醇MRA在一个大型现实世界HF队列中表现出优异的1年临床结果.
- 这些发现表明,非类固醇MRA在各种HF表型中具有显著的临床实用性.
- 需要进一步的随机试验来证实这些现实观察.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
01:22Heart Failure Drugs: β-Blockers
760
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
760
01:22Heart Failure Drugs: Diuretics
796
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
796
01:30Heart Failure V: Medical Management
215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K